Loading company…
Tokyo-based Noile-Immune Biotech develops CAR-T cell therapies for cancer using its NOILE and PRIME technologies.
Founded in 2015 and headquartered in Tokyo, Japan, Noile-Immune Biotech develops cancer immunotherapies, with a lead pipeline program, NIB-101, focused on gene-modified immune cell therapies. It serves hospitals, oncology clinics and biopharma partners in North America, Europe and parts of Asia. The company raised JPY 2.38 billion in Series C funding on March 22, 2021, led by Binex Holdings, Dai-ichi Life Insurance and Shibuya Corporation, and has completed five deals. Its fiscal 2020 revenue was JPY 983,493.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in